Reversible cardiac valvular disease in catastrophic antiphospholipid syndrome

Netherlands Journal of Medicine

Volumn 68, Issue 5, 2010, Pages 215-220

  Teunisse, C C ^a   Kalsbeek, A J ^b   de Vries, S T ^a   Huisman, S J ^b   Boers, J E ^c   Breeman, A ^a   Beukhof, J R ^b  

^a Departments of Cardiology   (Netherlands)

^b Internal Medicine   (Netherlands)

^c Pathology   (Netherlands)

Author keywords

Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Echocardiography; Heart valve diseases; Therapeutics; Valve regurgitation

Indexed keywords

ACENOCOUMAROL; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; LISINOPRIL; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY INTIMA PROLIFERATION; ARTHRALGIA; ARTICLE; BACTERIAL ENDOCARDITIS; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE REGURGITATION; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; KIDNEY BIOPSY; LABORATORY TEST; LUNG ARTERY PRESSURE; MALAISE; MITRAL VALVE REGURGITATION; ORGANIC PSYCHOSYNDROME; PHYSICAL EXAMINATION; PLASMAPHERESIS; PLEURA EFFUSION; PROTEINURIA; RESPIRATORY FAILURE; SYSTOLIC HEART MURMUR; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRICUSPID VALVE REGURGITATION; UROSEPSIS; COMPLICATION; VALVULAR HEART DISEASE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEART VALVE DISEASES; HUMANS;

EID: 77953304707     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphos-pholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
2. Cervera R, Bucciarelli S, Plasín MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the 'CAPS Registry'. J Autoimmun. 2009;32:240-245.
3. Piette JC. Syndrome catastrophique des anticorps antiphospholipides (APL). Abstract Actualités Néphrologiques Necker, Paris 2008.
4. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-1027.
5. Amigo MC. The Heart and APS. Clin Rev Allergy Immunol. 2007;32:178-183.
6. Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphos-pholipid syndrome. Lupus. 2005;14:691-696.
7. Van der Laan-Baalbergen NE, Mollema SA, Kritikos H, et al. Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus. Neth J Med. 2009;67:295-301.
8. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care. 2002;8:376-388.
9. Espinosa G, Bucciarelli S, Cervera R, Gómez-Puerta JA, Font J. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:68-71.
10. Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis. 2002;61:195-208.
11. Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol. 2004;31:2402-2407.
12. Mankad S, Khalil R, Kramer CM. MRI for the diagnosis of myocardial ischemia and viability. Curr Opin Cardiol. 2003;18:351-356.
13. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80:355-377.
14. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:98-103.
15. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
16. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-853.
17. Asherson RA, Cervera R, De Groot PG, et al. Catastrophic antiphos-pholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003;12(7):530-534.